

Salt Tolerant Microbes (Active Metabolites) Mediated Nanoparticle: Drug Delivery and Future Prospects

Priya¹, Poonam Joshi^{1*} , Jaya Rautela², Pallavi Pandey¹, Srishti Morris¹ and Pallavi Ghildiyal¹

¹Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun-248007, Uttarakhand, India.

²Department of Pharmaceutical Sciences, School of Health Science and Technology, UPES, Dehradun, Uttarakhand, India.

Abstract

Salt Tolerant Microbes are a group of microorganisms that grow, develop, and survive in extremely high salt concentrations. Based on their tolerance level they generally grow up optimally at pH values beyond 9.0, but the growth is inhibited at the pH value that is most closely associated with neutral 6.5. They have minimal dietary needs and a good salt quantity that is high enough to osmotic pressure. They can produce biological metabolites that have certain actions such as antibacterial, antifungal, antioxidant, and anticancer. We discussed in this article various pharmaceutical formulations of salt-tolerant microbes, every formulation shows the specific pharmacological actions like anti-cancer activity, anti-oxidant activity, and anti-microbial activity, and also discusses methods for the biosynthesis of salt-tolerant microbes' nanoparticles.

Keywords: Salt Tolerant Microbes, Nanoparticles, Metabolites, Microorganism

*Correspondence: poonamjoshi363602@gmail.com

Citation: Priya, Joshi P, Rautela J, Pandey P, Morris S, Ghildiyal P. Salt Tolerant Microbes (Active Metabolites) Mediated Nanoparticle: Drug Delivery and Future Prospects. *J Pure Appl Microbiol.* 2024;18(2):853-866. doi: 10.22207/JPAM.18.2.52

© The Author(s) 2024. **Open Access.** This article is distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

INTRODUCTION

Salt-tolerant microbes are divided into three main categories i.e., Mild, Moderate, and High. Salt Tolerant Microbes require levels of sodium chloride above 3% in salt water.¹ Several factors affect the tolerance criteria like growth medium, pH, temperature, and salt concentration. They generally grow up optimally at pH values beyond 9.0, but the growth is inhibited at the pH value that is most closely associated with neutral 6.5.^{2,3} The general mechanism followed by Salt Tolerant microbes for surviving in varying saline conditions.

They have minimal dietary needs and a good salt quantity that is high enough for osmotic pressure.⁴ The processes of their halo adaptation (halophilic bacteria can maintain growth and development under salinity conditions) on the internal storage of KCl (potassium chloride) approximately 37% or maintain the equilibrium of sodium ions in the cell plasma and resist the osmotic pressure of the outside surroundings caused by the excessive salinity.

These organisms act on an osmoregulatory mechanism that helps them to grow in acute concentration by balancing ion exchange with the surroundings and their tolerance along with surviving for a long-life span brings the Salt Tolerant Microbes into a new era of development.⁵⁻⁸

Hypersaline regions offer several possibilities for the production of additional metabolites with industrially relevant bioactivities.^{9,10}

The secondary metabolites produced by the Salt Tolerant Microbes show properties against drug-resistant bacteria. Using these metabolites with the help of nanotechnology will be used as a powerful tool in pharmaceutical sciences.¹¹⁻¹³

They can produce biological metabolites that have certain actions such as antibacterial, antifungal, antioxidant, and anticancer. The overuse of basically antibiotic drugs has resulted in the development of drug resistance (DR), which reduces or eliminates their efficacy.^{14,15} The DR is shown in the human body (Cancer cells and micro-organisms). So, to overcome DR issues

Table 1. Various nano-formulations of Salt Tolerant Microbes

Targeted delivery	Salt Tolerant Microbes	Nano-formulations	Ref.
Anticancer	<i>Archaeal halophile</i> <i>Haloarchaea</i> <i>Halomonas elongata</i> .	nanoparticles synthesis, and gas vesicles Silver nanoparticles Selenium nanoparticles (antibacterial and antioxidant)	29
Antimicrobial	<i>Ideomarina species</i> <i>Halophilic Archaea</i> <i>Chromohalobacter salexigens</i> , <i>Halobacillus halophilus</i> , and <i>Halomonas elongate</i> <i>Archaeal Salt Tolerant Microbes Halophilic archaeon Extremophilic bacterium-A30</i> <i>Archaeobacteria, actinomycetes, cyanobacteria</i> , and fungi.	Selenium nanoparticles Encapsulation of carotenoids isolated from halophilic Archaea in oil-in-water (O/W) nano- and micro-emu Ectoine nasal spray Nanoparticles synthesis, and gas vesicles Gas vesicle nanoparticles Silver nanoparticles Silver nanoparticles	30, 31
Antioxidants	<i>Streptomyces Marietta</i> , <i>Bacillus subtilis</i> , <i>Bacillus tequilensis</i> , and <i>Bacillus Haynes</i> <i>Haloferax volcanii</i> BBK2, <i>Haloarcula japonica</i> BS2, and <i>Halogeometricum borinquense</i> E3	Methanolic extract of halophilic bacterial strain Nanoneedles and selenium nanospheres	32, 33, 34

advanced technologies have been introduced example drug-resistant strains using biomaterials and metabolites. The challenge is to overcome the difficulties related to drug resistance not only in animals and environmental aspects but also in humans. Two types of genes are responsible for resistance, where the first is horizontal gene transfer (HGT) and the second is genes that are already encoded in the bacterial genome that can give antibiotic resistance by mutation and activation of mobile elements. The recent drug resistance example is third-generation cephalosporin caused by a mutation in genes encoding penicillin-inactivating enzyme. The invention of new medications is necessary to overcome DR issues for better treatment and the Salt Tolerant Microbes (active metabolites) nanoparticles attracted a lot of attention. Some examples of DR have been observed in clinical

strains against various antibiotics, affecting both gram-negative and gram-positive bacteria. Resistance is perceived in *Haemophilus influenza* to ampicillin, in *Helicobacter pylori* to clarithromycin and in *Staphylococcus aureus* shows intermediate resistance to vancomycin. *Pseudomonas aeruginosa* and *Neisseria gonorrhoeae* to aminoglycosides and quinolone, *Enterobacteriaceae* to cephalosporins and carbapenems. Furthermore, *Enterococcus faecium* exhibits resistance to cephalosporin and vancomycin, whereas *Streptococcus pneumoniae* discerns resistance to penicillin. Unexpectedly, the quorum-sensing mechanism of *Pseudomonas aeruginosa* led to the development of fluconazole resistance in *Candida albicans*. In response to these challenges, there has been a growing interest in utilizing halophilic biomolecules to combat DR bacteria.¹⁶⁻²⁰





Table 2. Methodology and Key Findings (application) of Biosynthesized Nano-particles

No.	Methods	Key- findings	Ref.
1.	Dynamic aggregation with radiation-induced cross-linking	Drug carrier	35-39
2.	Genetically encoded synthesis in <i>E. coli</i>	Treatment of cancer-conjugated drug	40, 41
3.	Electrospraying	Doxorubicin drug delivery model: ph-responsive drug	42-46
4.	Ionic gelatin	Delivery of hydrophobic bioactive compounds	47
5.	Redox reaction	Anti-cancer treatment	48
6.	One pot synthesis	Platinum drugs delivery to cancerous cells	49, 50
7.	Lyophilization	Treatment of breast cancer	51
8.	Ring-opening polymerization	Drug delivery for prostate carcinoma	52
9.	Self-assembly	Biosensors	52

Table 3. Anti-cancer activity of a few Active Metabolites of Salt Tolerant Microbes with targeted deliveries







No.	Salt Tolerant Organism	Metabolite	Targeted Delivery	Ref.
1.	<i>Bacillus</i> species	3-Methyl-2(2-isopropyl) furan	Cervical carcinoma	53
2.	<i>Nocardiosis</i> species HYJ128	Borrelidin C, Borrelidin D	Stomach and leukemia carcinoma	54
3.	<i>Streptomyces</i> sp.	Salternamide A	Colorectal and gastric cancer	55
4.	<i>Streptomyces</i> species WH26	Naphthomycin	Lung adenocarcinoma, cervical carcinoma	56
5.	<i>Nocardiosis</i> species	Methyltetrangomycin	Liver cancer	56





Table 4. Active metabolites of Halophilic micro-organisms responsible for anti-oxidant activity








Salt Tolerant Microbes	Structure/ metabolite	Antioxidant assay	Free radical cleavage capacity	Ref.
Nocardopsis gilva YIM 90087		DPPH / ABTS	54.9±2.0% at 2 mg/mL in DPPH 68.6±1.0 at 1 mg/mL in ABTS	57
		DPPH / ABTS	14.3 ± 1.5% at 4 mg/mL 28.4±2.7 at 2 mg/mL in ABTS	
		DPPH/ ABTS	47.7±0.9% at 2 mg/mL 78.2±3.7 at 0.5 mg/mL in ABTS	
		ABTS	54.6±0.6% at 2 mg/mL	
Halophilic Archaea	C50 carotenoids	EPR spectroscopy	43.17±1.79 of microemulsion and 66.08±0.25 of Nanoemulsion (5 min) 82.38±0.13 of microemulsion and 87.98±2.13 of Nanoemulsion (30 min)	57

<i>Haloterrigena turkmenica</i>	Carotenoids (BR, MABR, and BABR)	DPPH / FRAP	66.8%±1.2 with DPPH	57
<i>Halomonas nitroreducens</i> strain WB1	EPS (glucose, mannose, galactose, rhamnose, arabinose)	Hydroxyl radical scavenging activity, DPPH radical scavenging activity	0.067±0.008 at 0.2 µg with FRAP 5.0 mg/ml show 83.3%	58
<i>Phialosimplex</i> species	-	DPPH, OH ⁻ , b-carotene antioxidant	450.92±6.73 (mg/ml), 390.97±3.97 (mg/ml), 36.59±2.94(mg/ml) respectively	58
<i>Nesterenkonkia</i> species	HJ01pe	DPPH, ABTS	37.7±1.7 and 16.2±0.5 respectively	58
<i>Staphylococcus Arlette</i>	-	ABTS, nitric oxide, phosphomolybdenum, FRAP, and DPPH	86.34±0.007 mM TE/g extract with ABTS 64.79±0.004 µg/ml with nitric oxide 1.69±0.024 mg AAE/g extract with phosphomolybdenum 28.19±0.012 mM Fe (II) E/mg with FRAP 5.48 mg/ml with DPPH	59
<i>Haloarcula</i> species	-	ABTS	95.6± 0.1 at 200 004 µg/ml	59
<i>Halorubrum</i> species HRM-150	bacterioruberin (84.12 %), followed by mono anhydriobacterioruberin(15.13 %) and carotenoid extract	2,2-azinobis-3-ethyl-b enzo-thiazole-6-sulfonicacid, 2,2-diphenyl-1-picrylhydrazyl, and hydroxylradicals.	Bacterioruberin shows better antioxidant activity	59
<i>Aspergillus terreus</i> Tsp22	Crude extracellular compounds	-	-	60
<i>Aspergillus flavus</i> , <i>Aspergillus gracilis</i> , <i>Aspergillus penicilliosis</i>	-	-	-	60
<i>Halogeometricum limi</i> strain RO1-6	-	1,1-diphenyl-2-picrylhydrazyl radical scavenging assay.	-	60
<i>Haloplanus vesicus</i> strain RO5-8	-	-	-	60

Table 5. Salt Tolerant Microbes metabolites examples with antimicrobial activities


No	Salt Tolerant Microbes Organisms	Metabolite	Activity	Ref.
1	<i>Nocardiopsis</i> species	 <p>Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl)</p>	Antibacterial	61
2	<i>Bacillus subtilis</i>	 <p>(E)-docos-13-enamide</p>  <p>octadec-9-enamide</p>	Antibacterial, antifungal	61
3	<i>Aspergillus flocculosus</i>	 <p>4-methoxy-3-[(1E,3Z,5E)-6-(1H-pyrrol-2-yl)hexa-1,3,5-trienyl]pyran-2-one</p>	Antibacterial	61
4	<i>Bacillus subtilis</i>	<p>Glycoprotein</p> <p>Quinoloid alkaloid,</p> 	Antibacterial, antifungal	62
5	<i>Nocardiopsis terrae</i>	<p>4-oxo-1,4-dihydroquinoline-3-carboxamide</p>  <p>Indole-3-carboxylic acid</p>	Antibacterial and anticancer	62
6	<i>Halomonas salaria</i>	<p>Amylase</p> <p>Protease</p> <p>8-anilino-naphthalene-1-sulfonic acid (lipase) (2S, 3R,4S,5S,6R)-2-[(2R,3S,4R, 5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6 [(2R,3S, 4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3, 4,5-triol (cellulase)</p> <p>Pectinase DNAase</p>	Antimicrobial	62

7	<i>Actinomyces</i> species	 <p>2-chloroacetate</p> <p>ethyl 2-chloroacetate</p> <p>(3R)-4-chloro-3-hydroxybutanenitrile</p>	Antimicrobial	62
8	<i>Bacillus subtilis</i>	<p>Carotenoids Polyhydroxy alkanoates</p>	Antibacterial	63
9	<i>Halomonaselongata</i>	 <p>(6S)-2-methyl-1,4,5,6-tetrahydropyrimidine-6-carboxylic acid</p>	Antimicrobial	63
10	<i>Halobacilluskarajiensis</i>	Peptide furanomycin	Antimicrobial	63
11	<i>Vibrio parahaemolyticus</i> B2	 <p>3-[1-(1H-indol-3-yl)ethyl]-1H-indole</p> <p>Himalomycin A</p>	Antimicrobial	63
12	<i>Streptomyces</i> species B6921	 <p>himalomycin B</p> <p>Fridamycin D</p>	Antimicrobial	64

13 <i>Actinomadura</i> species M048		Antimicrobial	64
	N-(9-hydroxy-3-oxophenoxazin-2-yl)acetamide		
	Chandrananimycin A		
			
	2-hydroxy-N-(3-oxophenoxazin-2-yl)acetamide		
	Chandrananimycin B		
			
	1-methoxy-3-methyl-1,2,3,4-tetrahydropyrido[3,2-a]phenoxazin-5-one		
	Chandrananimycin C		
	Nitro-tetraene Spiro-beta-lactone-gamma-lactum		
14 <i>Streptomyces nodosus</i> NPS007994		Antimicrobial	64
	Lajollamycin		
15 <i>Streptomyces chibaensis</i> species AUBN1/7		Antimicrobial	64
	1-Hydroxy-1-norresistomycin		
16 <i>Vibriosp.</i> A1SM3-36-8		Antibacterial	65
	13-cis-docosenamide		
17 <i>Pseudonocardia</i> <i>endophytica</i> VHK-10		Antimicrobial	66
	3-((1H-indol-6-yl) methyl) hexahydropyrrolo (1,2-a) pyrazine-1,4-dione		
18 <i>Halobacillus karajiensis</i> , <i>Alkalibacillus almallahensis</i>	Peptide furanomycin	Antimicrobial	66

19 *Streptomonosporaalba*

Antibacterial 67




(Streptomonicin)


20 *Streptomyces* species
CNQ-418

Marinopyrroles A
Marinopyrroles B


Antibacterial 67




Lynamicin A




Lynamicin B



Lynamicin C



Lynamicin D




Lynamicin E

21 *Marinispora* species
NPS12745

Antimicrobial 68,69

22 *Streptomyces hygroscopicus* BDUS 49



7-Demethoxy-7-(2-furyl) rapamycin

Antimicrobial 69

Nano formulation of existing salt tolerant microbes for the targeted diseases

Several factors are required for the biosynthesis and formulation of bioactive metabolites for example uniform size, high purity, and composition for synthesis through selected techniques.^{21,22}

Various existing nanoformulations of Salt Tolerant Microbes with different targeted delivery like anticancer, antimicrobial, and antioxidant are discussed in Table 1.

Different methods for preparing nanoparticles with key findings are discussed in Table 2.

Currently, the nano-formulation of Salt Tolerant Microbes' active metabolites is considered a scientific tool in the pharmaceutical field. The current approach is focused on treating antibiotic resistance. The study suggests that the metabolite of Salt Tolerant Microbes produced due to the lack of nutrients, starvation, dehydration, UV-rays, and imbalanced ion concentration makes them deserving candidates for drug discovery. Some examples are also discussed like Anti-cancer activity (Table 3), and anti-oxidant activity (Table 4) in the table we also discuss some tests of anti-oxidant activity like DPPH stands as 2,2-diphenyl-1-picrylhydrazyl is a chemical compound commonly used to measure the antioxidant properties of a substance. The principle behind the DPPH assay is to determine antioxidant properties, through which antioxidant substances will neutralize the free radical of DPPH. ABTS stands for (2,2-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid)), and it measures the ability of antioxidants to scavenge free radicals and prevent oxidation. It observed the reduction of the blue-green color of the

solution. The nitric oxide test is used to measure the antioxidant activity of a substance. Nitric oxide is a free radical on which different substances are tested to determine their antioxidant properties by using various methods such as the Griess reagent method.

Anti-microbial activity (Table 5) of a few Active Metabolites of Salt Tolerant Microbes with targeted deliveries. The production of carotenoid colors, retinal amino acids, hydrolytic enzymes, and suitable solutes like macromolecule stabilizing agents, biopolymers, and biofertilizers by halophilic microbes is well known. The production of bioplastics, artificial retinas, photoelectric devices, holograms, biological sensors, and other products uses salt-tolerant microbes and extremely halophilic aerobic archaea, also known as haloarchaea, plays a significant role in the industry.²³⁻²⁸

Future perspective

Public health is currently at risk due to the widespread development of antibiotic resistance. Millions of lives have been saved by antibiotics over the years, yet overuse of these drugs has resulted in the development of multi-drug resistant (MDR), which reduces or eliminates their efficacy. Antibiotic resistance has recently reached critical levels, indicating a rise in fatality in the healthy community and a near-term concern for hospitalized patients. In actuality, problems with MDR infections can cause the majority of patient deaths. The exploitation of all organic and environmentally friendly assets, including major environments as an opportunity for new antibiotic discoveries, is being prompted by the urgent need to develop new antimicrobial medicines that are

effective and safe. In 1982, Rodriguez-Valera et al reported the discovery of the first antibacterial substances produced by salt-tolerated microbes. Halocin is the name given to compounds released by numerous Halobacterium species that can lyse and kill the local microbiota. Haloarchaea synthesize peptides and antimicrobial peptides (AMPs) known as halocins. Although some halocins play an ecological and environmental role, less research has been done on how they interact with human infections.⁷⁰

The clinical significance of salt-tolerated microorganisms is rarely described in the race against time, and antimicrobial intervention against the most significant risk category of human pathogens is lacking. *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Enterococcus faecium*, and *Pseudomonas aeruginosa* are still potential pathogens.⁷¹

In the generation of advancement, nanotechnology has been proven as the speedily evolving field that deals with the size of material 1 to 100 nm in diameter. biomolecules like proteins, nucleic acid, lipids, and polysaccharides are proven to be found in nature and can be used in the development of nanoparticles because they possess their individual properties. To develop distinctive works of art and purpose biomolecules can be engineered with nanoparticles which can result in a Novel Biomolecule Nanoparticle hybrid. So far, there are limited articles available for biomolecule nanoparticles and Salt Tolerant Microbes that can be persuaded for the creation of drug-resistant bacteria to make a variety of antibacterial drugs and anti-cancer drugs. hence, contemporary information on the technology and current trends in an individual field is required. the present review is about the Salt Tolerant Microbes and the metabolites formed by them and integrating them with nanotechnology to form biological nanoparticles which can be considered as new trends in the field of medicine and pharmaceutical field.⁷²

CONCLUSION

As this review proceeds, the study focuses on the Salt Tolerant Microbes, their origin, and the mechanism through which they survive in extreme saline conditions. along with they also

produce bioactive agents with significant uses and applications in the pharmaceutical and healthcare area. Salt Tolerant Microbes show diverse significance in the production of bioactive compounds that show therapeutic properties such as antioxidant, antimicrobial, and anti-cancer. Due to their more distinctive properties, these can be considered novel drugs. A further highlight is to focus the beam toward the integration and conjugation of these bioactive substances with nanoparticles for novel perception. The nanotechnology to form salt-tolerant microbes-mediated nanoparticles can be considered a new trend in the pharmaceutical field. This study will also be helpful in the MDR of antibiotics in the pharmaceutical field.

ACKNOWLEDGEMENTS

None.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHORS' CONTRIBUTION

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

None.

DATA AVAILABILITY

All datasets generated or analyzed during this study are included in the manuscript.

ETHICS STATEMENT

Not applicable.

REFERENCES

1. Abdollahnia M, Makhdoumi A, Mashreghi M, Eshghi H. Exploring the potentials of halophilic prokaryotes from a solar saltern for synthesizing nanoparticles: The case of silver and selenium. *PLoS One*. 2020;15(3):e0229886. doi: 10.1371/journal.pone.0229886
2. Abirami G, Ramprasath C, Arthi, Mathivanan N. Anticandidal activity of halophilic bacterium *Vibrio azureus* MML1960 isolated from Kelambakkam Saltpan, Tamil Nadu, India. *India Res J Biotechnol*. 2018;13(2):8-20.
3. Ahmed S, Ahmed M Z, Rafique S, et al. Recent

- approaches for downplaying antibiotic resistance: Molecular mechanisms. *BioMed Res Int*. 2023;2023:5250040. doi: 10.1155/2023/5250040
4. Alavi M, Thomas S, Sreedharan M. Modification of silica nanoparticles for antibacterial activities: mechanism of action. *Micro Nano Bio Aspects*. 2022;1(1):49-58. doi: 10.22034/MNBA.2022.153448
 5. Al-Kordy MH, Sabry HA, Mabrouk S. Photocatalytic and antimicrobial activity of zinc oxide nanoparticles synthesized by halophilic *Alkalibacillus* sp. w7 isolated from a salt lake. *Egyptian Journal of Aquatic Biology and Fisheries*. 2020;24(4):43-56. doi: 10.21608/ejabf.2020.94732
 6. Arul D, Balasubramani G, Balasubramanian V, Natarajan T, Perumal P. Antibacterial efficacy of silver nanoparticles and ethyl acetate's metabolites of the potent halophilic (marine) bacterium, *Bacillus cereus* A30 on multidrug-resistant bacteria. *Pathog Glob Health*. 2017;111(7):367-382. doi: 10.1080/20477724.2017.1390829
 7. Aslam S, Sajid I. Antimicrobial potential of halophilic actinomycetes isolated from a saline lake against various multi-drug resistant bacterial pathogens causing ventilator-associated pneumonia. *Int J Infect Dis*. 2014;21(S1):205. doi: 10.1016/j.ijid.2014.03.850
 8. Chaari M, Theochari I, Papadimitriou V, Xenakis A, Ammar E. Encapsulation of carotenoids extracted from halophilic Archaea in oil-in-water (O/W) micro- and nano-emulsions. *Colloids Surf B Biointerfaces*. 2018;161:219-227. doi: 10.1016/j.colsurfb.2017.10.042
 9. Chen J, Cong X. Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects. *Biomed Pharmacother*. 2023;157:113998. doi: 10.1016/j.biopha.2022.113998
 10. Corral P, Amoozegar MA, Ventosa A. Halophiles and their biomolecules: Recent advances and future applications in biomedicine. *Marine Drugs*. 2020;18(1):33. doi: 10.3390/md18010033
 11. Das A, Satyaprakash K, Das AK. Extremophilic fungi as a source of bioactive molecules. *Extremophilic Fungi*. Springer Nature Singapore. 2022:489-522. doi: 10.1007/978-981-16-4907-3_21
 12. Dutta B, Bandopadhyay R. Biotechnological potentials of halophilic microorganisms and their impact on mankind. *Beni Suef Univer J Basic Appl Sci*. 2022;11(1):75. doi: 10.1186/s43088-022-00252-w
 13. Elyasifar B, Jafari S, Hallaj-Nezhadi S, Chapeland-Leclerc F, Ruprich-Robert G, Dilmaghani A. Isolation and identification of antibiotic-producing halophilic bacteria from dagh barmaid and haj aligholi salt deserts, Iran. *Iran Pharm Sci*. 2019;25(1):70-77. doi: 10.15171/ps.2019.11
 14. Fareed N, Nisa S, Bibi Y, et al. Green synthesized silver nanoparticles using carrot extract exhibited strong antibacterial activity against multidrug-resistant bacteria. *J King Saud Univ Sci*. 2023;35(2):102477. doi: 10.1016/j.jksus.2022.102477
 15. Gagliardi A, Giuliano E, Venkateswararao E, et al. Biodegradable polymeric nanoparticles for drug delivery to solid tumors. *Front Pharmacol*. 2021;12:601626. <https://doi.org/10.3389/fphar.2021.601626>
 16. Giani M, Montoyo-Pujol YG, Peiro G, Maria Martinez-Espinosa RM. Halophilic carotenoids and breast cancer: From salt marshes to biomedicine. *Marine Drugs*. 2021;19(11):594. doi: 10.3390/md19110594
 17. Giordano D. Bioactive Molecules from Extreme Environments. *Marine Drugs*. 2020;18(12):640. doi: 10.3390/md18120640
 18. Giordano D. Bioactive molecules from extreme environments II. *Marine Drugs*. 2021;19(11):642. doi: 10.3390/md19110642
 19. Girao M, Ribeiro I, Carvalho M de F. Actinobacteria from marine environments: A unique source of natural products. *Natural Products from Actinomycetes Springer* Singapore. 2022:1-45. doi: 10.1007/978-981-16-6132-7_1
 20. Gocheva Y, Angelova M, Krumova E. Potential of Halotolerant and Halophilic Fungi as a Source of New Extracellular Enzymes and Antimicrobial Compounds. *Acta Microbiol Bulg*. 2021;37(2):57-68.
 21. Huang SJ, Wang TH, Chou YH, et al. Hybrid PEGylated chitosan/PLGA nanoparticles are designed as pH-responsive vehicles to promote intracellular drug delivery and cancer chemotherapy. *Int J Biol Macromol*. 2022;210:565-578. doi: 10.1016/j.ijbiomac.2022.04.209
 22. Huang SX, Zhao LX, Tang SK, Jiang CL, Duan Y, Shen B. Erythronolides H and I, new erythromycin congeners from a new halophilic actinomycete *Actinopolyspora* sp. YIM90600. *Organic Letters*. 2009;11(6):1353-1356. doi: 10.1021/ol900143j
 23. Hui M L Y, Tan L TH, Letchumanan V, et al. The extremophilic Actinobacteria: From microbes to medicine. *Antibiotics* (Basel, Switzerland). 2021;10(6):682. doi: 10.3390/antibiotics10060682
 24. Ibrahim KS, Aishwarya M, Kannan RP. Secondary Metabolites from Extremophiles with Therapeutic Benefits. *Recent Advances and Future Perspectives of Microbial Metabolites*. 2023. doi: 10.1016/B978-0-323-90113-0.00011-0
 25. Jose PA, Santhi VS, Jebakumar SRD. Phylogenetic-affiliation, antimicrobial potential and PKS gene sequence analysis of moderately halophilic Streptomyces sp. inhabiting an Indian saltpan. *J Basic Microbiol*. 2011;51(4):348-356. doi: 10.1002/jobm.201000253
 26. Kim J, Shin D, Kim SH, et al. Borrelidins C-E: New antibacterial macrolides from a saltern-derived halophilic *Nocardiopsis* sp. *Mar Drugs*. 2017;15(6):166. doi: 10.3390/md15060166
 27. Kim SH, Shin Y, Lee SH, et al. Salternamides A-D from a halophilic *Streptomyces* sp. Actinobacterium. *J Nat Prod*. 2015;78(4):836-843. doi: 10.1021/acs.jnatprod.5b00002
 28. Lin Z, Wu G, Zhao L, Lai KWC. Detection of bacterial metabolic volatile indole using a graphene-based field-effect transistor biosensor. *Nanomaterials* (Basel, Switzerland). 2021;11(5):1155. doi: 10.3390/nano11051155
 29. Liu H, Xiao L, Wei J, et al. Identification of Streptomyces sp. nov. WH26 producing cytotoxic compounds isolated from marine solar saltern in China. *World*

- J Microbiol Biotechnol.* 2013;29(7):1271-1278. doi: 10.1007/s11274-013-1290-8
30. Liu N, Cui T, Gao X, Zhu D, Xing J. Advances in the biomedical application research of halophilic microorganisms. *Sheng wu gong cheng xue bao.* 2022;38(6):2153-2168. doi: 10.13345/j.cjb.210928
31. Manivasagan P, Oh J. Marine polysaccharide-based nanomaterials as a novel source of nanobiotechnological applications. *Int J Biol Macromol.* 2016;82:315-327. doi: 10.1016/j.ijbiomac.2015.10.081
32. Meena B, Anburajan L, Vinitkumar NV, Kirubakaran R, Dharani G. Biodiversity and antibacterial potential of cultivable halophilic actinobacteria from the deep sea sediments of active volcanic Barren Island. *Microbial Pathogenesis.* 2019;132:129-136. doi: 10.1016/j.micpath.2019.04.043
33. Metevlev M, Tietz JI, Melby JO, et al. Structure, bioactivity, and resistance mechanism of streptomycin, an unusual lasso Peptide from an understudied halophilic actinomycete. *Chem Biol.* 2015;22(2):241-250. doi: 10.1016/j.chembiol.2014.11.017
34. Al-shaibani MM, Radin Mohamed RMS, Sidik NM, et al. Biodiversity of secondary metabolites compounds isolated from phylum actinobacteria and its therapeutic applications. *Molecules.* 2021;26(15). doi: 10.3390/molecules26154504
35. Mohammadipناه F, Hamed J, Dehghani M. Halophilic bacteria: Potentials and applications in biotechnology. *Sustainable Development and Biodiversity.* 2015:277-321. doi: 10.1007/978-3-319-14595-2_11
36. Moopantakath J, Imchen M, Anju VT, et al. Bioactive molecules from haloarchaea: Scope and prospects for industrial and therapeutic applications. *Front Microbiol.* 2023;14:1113540. doi: 10.3389/fmicb.2023.1113540
37. Mukherjee S, Atique U, Mukherjee R, et al. Potential of extremophiles: a review of current research in nanoparticle synthesis. *Extremophiles.* 2022:289-314. doi: 10.1515/9783110788488-014
38. Niyasom C, Mamimin C. Antimicrobial activity of extremely Halophilic Archaea isolated from Southern Thai salt-fermented products and solar saltern of pattani, Thailand. *ASEAN Journal of Scientific and Technological Reports.* 2023;26(2):30-38. doi: 10.55164/ajstr.v26i2.248121
39. Patankar R P Zambare V, Ponraj M. Physiological aspects of the halophilic and halotolerant fungi, and their potential applications. *Novel Research in Microbiology Journal.* 2021;5(5):1371-1391. doi: 10.21608/nrmj.2021.199315
40. Rathod MG, Kamble GT, Dhawale PI, et al. Halophilic microbiome: Distribution, diversity, and applications. *World J Adv Res Rev.* 2023;17(1):926-933. doi: 10.30574/wjarr.2023.17.1.0117
41. Rodriguez-Carmona E, Villaverde A. Nanostructured bacterial materials for innovative medicines. *Trends Microbiol.* 2010;18(9):423-430. doi: 10.1016/j.tim.2010.06.007
42. Romero EL, Morilla MJ. Ether lipids from archaea in nano-drug delivery and vaccination. *Int J Pharm.* 2023;634:122632. doi: 10.1016/j.ijpharm.2023.122632
43. Lakshmi A, Sheeja L, Mari SD. Screening and identification of asparaginase and glutaminase producing halophilic bacteria from natural saline habitats. *Int J Recent Adv Biotechnol Nanotechnol.* 2020;3:34-53.
44. Ruwandeepika HAD, Fernando GCP, Jayaweera TSP. An overview of biomedical, biotechnological, and industrial applications of Actinomycetes. *Natural Products from Actinomycetes, Springer* Singapore. 2022: 475-508. doi: 10.1007/978-981-16-6132-7_18
45. Sepcic K, Zalar P, Gunde-Cimerman N. Low water activity induces the production of bioactive metabolites in halophilic and halotolerant fungi. *Mar Drugs.* 2010;9(1):43-58. doi:10.3390/md9010043
46. Saallah S, Lenggoro IW. Nanoparticles carrying biological molecules: Recent advances and applications. *Kona: Powder Science and Technology in Japan.* 2018;35:89-111. doi: 10.14356/kona.2018015
47. Sachin K, Karn SK. Microbial fabricated nanosystems: Applications in drug delivery and targeting. *Front Chem.* 2021;9:617353. doi: 10.3389/fchem.2021.617353
48. Salehghamari E, Taheri F, Hosseini M, et al. Interspecies interactions of halophilic and halotolerant actinomycetes: An example from a salt. *Progress in Biological Sciences.* 2017;7:183-189.
49. Salem NFA, Abouelkheir SS, Yousif AM, et al. Large scale production of superparamagnetic iron oxide nanoparticles by the haloarchaeon *Halobiforma* sp. N1 and their potential in localized hyperthermia cancer therapy. *Nanotechnology.* 2021;32(9):09LT01. doi: 10.1088/1361-6528/abc851
50. Santhaseelan H, Dinakaran VT, Dahms HU, et al. Recent antimicrobial responses of halophilic microbes in clinical pathogens. *Microorganisms.* 2022;10(2):417. doi: 10.3390/microorganisms10020417
51. Sarkar G, Suthindhiran K. Diversity and biotechnological potential of marine *Actinomycetes* from India. *Indian J Microbiol.* 2022;62(4):475-493. doi: 10.1007/s12088-022-01024-x
52. Safarpour A, Ebrahimi M, Fazeli SAS, Amoozegar MA. A phenol amine molecule from *Salinivenuus iranica* acts as the inhibitor of cancer stem cells in breast cancer cell lines. *Sci Rep.* 2023;13(1):12669. doi:10.1038/s41598-023-39736-9
53. Shakibaie M, Salari Mohazab N, Ayatollahi Mousavi SA. Antifungal Activity of Selenium Nanoparticles Synthesized by *Bacillus* species Msh-1 Against *Aspergillus fumigatus* and *Candida albicans*. *Jundishapur J Microbiol.* 2015;8(9):e26381. doi: 10.5812/jjm.26381
54. Shantkriti S, Pradeep M, Unish KK, et al. Bioynthesis of silver nanoparticles using *Dunaliella salina* and its antibacterial applications. *Appl Surf Sci Adv.* 2023;13:100377. doi: 10.1016/j.apsadv.2023.100377
55. Sharma C, Chaturvedi P, Mathur P, Mathur N, Bhatnagar P. Halophilic and halotolerant Actinomycetes of Sambhar Salt Lake, India: Screening and optimization of cellulolytic activity. *J Pure Appl Microbiol.* 2022;16(3):1809-1825. doi: 10.22207/jpam.16.3.24
56. Shi T, Wang YF, Wang H, Wang B. Genus *Nocardioopsis*: A prolific producer of natural products. *Marine Drugs.* 2022;20(6):374. doi: 10.3390/md20060374
57. Siddique MH, Hayat S, Muzammil S, et al. Ecofriendly phytosynthesized zirconium oxide nanoparticles as

- antibiofilm and quorum quenching agents against *Acinetobacter baumannii*. *Drug Development and Industrial Pharmacy*. 2022;48(9):502-509. doi: 10.1080/03639045.2022.2132260
58. Singh AK, Tiwari R, Singh VK, et al. Green synthesis of gold nanoparticles from *Dunaliella salina*, its characterization and *in vitro* anticancer activity on breast cancer cell line. *J Drug Deliv Sci Technol*. 2019;51:164-176. doi: 10.1016/j.jddst.2019.02.023
59. Srivastava P, Kowshik M. Anti-neoplastic selenium nanoparticles from *Idiomarina* sp. PR58-8. *Enzyme Microb Technol*. 2016;95:192-200. doi: 10.1016/j.enzmictec.2016.08.002
60. Tabibi M, Aghaei SS, Amoozegar MA, Nazari R, Zolfaghari MR. Antibacterial, antioxidant, and anticancer activities of biosynthesized selenium nanoparticles using two indigenous halophilic bacteria. *Archives of Hygiene Sciences*. 2020;9(4):275-286. doi: 10.52547/archhygsci.9.4.275
61. Tian SZ, Pu X, Luo G, et al. Isolation and characterization of new p-Terphenyls with antifungal, antibacterial, and antioxidant activities from halophilic actinomycete *Nocardiosis gilva* YIM 90087. *J Agric Food Chem*. 2013;61(12):3006-3012. doi: 10.1021/jf400718w
62. Tiquia-Arashiro S, Rodrigues D. Halophiles in Nanotechnology. *Extremophiles: Applications in Nanotechnology*, Springer. 2016:53-88. doi: 10.1007/978-3-319-45215-9_2
63. Vahabi L, Ranjbar PR, Davar F. Cladosporium protease/doxorubicin decorated Fe₃O₄@ SiO₂ nanocomposite: An efficient nanoparticle for drug delivery and combating breast cancer. *J Drug Deliv Sci Technol*. 2023;80:104144. doi: 10.1016/j.jddst.2022.104144
64. Zelante T, Puccetti M, Giovagnoli S, Romani L. Regulation of host physiology and immunity by microbial indole-3-aldehyde. *Curr Opin Immunol*. 2021;70:27-32. doi: 10.1016/j.coi.2020.12.004
65. Martin-Gallausiaux C. Butyrate produced by commensal bacteria down-regulates indoleamine 2, 3-dioxygenase 1 (IDO-1) expression via a dual mechanism in human intestinal epithelial cells. *Frontiers in Immunology*. 2018;9.
66. Wang YN, Meng LH, Wang BG. Progress in research on bioactive secondary metabolites from deep-sea derived microorganisms. *Marine Drugs*. 2020;18(12):614. doi: 10.3390/md18120614
67. Wei J, Zhu L, Lu Q, et al. Recent progress and applications of poly (beta-amino esters)-based biomaterials. *J Control Release*. 2023;354:337-353. doi: 10.1016/j.jconrel.2023.01.002
68. Zaramona I, Correia DM, Moreira J, et al. Magnetically responsive chitosan-pectin films incorporating Fe₃O₄ nanoparticles with enhanced antimicrobial activity. *Int J Biol Macromol*. 2023;227:1070-1077. doi: 10.1016/j.ijbiomac.2022.11.286
69. George J. Bioactive Screening and Antimicrobial Activity of Selected Three Medicinal Plants on Chosen Microbes. *Res J Pharm Tech*. 2014;7(11):1264-1269.
70. Sarvari S, Seyedjafari E, Amoozgar MA, Bakhshandeh B. The effect of moderately halophilic bacteria supernatant on proliferation and apoptosis of cancer cells and mesenchymal stem cells. *Cell Mol Biol (Noisy-le-grand)*. 2015;61(3):30-34.
71. Rajarajan S, Chandramouli R. Preparation, Numerical Optimization and Evaluation of Ciprofloxacin PLGA and PLA Nanoparticles by Solvent Displacement Technique. *Res J Pharm Tech*. 2009;2(1):186-190.
72. Samuel P, Kumar JV, Selvarathnam T, Deenadhayalan R, Amirtharaj K. Bioprospecting of marine halophyte *Salicornia europaea* L. and evaluation of its biological potential with special reference to anticancer activity. *Indian Drugs*. 2018;55(5):47-56. doi:10.53879/id.55.05.11115